• Ritlecitinib improves SALT scores in patients with alopecia areata

    1 day ago - By Healio

    MILAN - Severity of alopecia areata as well as scalp hair regrowth continued to improve with treatment at 48 weeks in further analysis of data from the ALLEGRO trial, according to a poster presented here.
    “Alopecia areata is an autoimmune disease that has an underlying immunoinflammatory pathogenesis and is characterized by nonscarring hair loss ranging from small patches to complete scalp, face and body hair loss,” Ulrike Blume-Peytavi, MD, and colleagues wrote in their presentation at the European Academy of Dermatology and Venereology Congress. “In this post hoc
    Read more ...